Skip to main content
Signal8
Launch Terminal

Vericel Corp (VCEL)

Vericel Corporation operates as a biopharmaceutical firm that has reached the commercialization phase, specializing in the research, development, production, and distribution of cell-based treatments. Its primary therapeutic areas are sports medicine and critical burn care across the United States. The company's product lineup includes MACI, an autologous cellularized scaffold employed for mending symptomatic, full-thickness cartilage damage in the knee, and Epicel, a permanent skin replacement designated as a humanitarian use device for treating deep-dermal or full-thickness burns in both adults and children. Additionally, Vericel is progressing NexoBrid, an orphan biological product currently in the registration phase, which aims to remove eschar from deep partial-thickness or full-thickness thermal burns in adults. Established in 1989 under its former name, Aastrom Biosciences, Inc., the company is headquartered in Cambridge, Massachusetts.

Sector: Biological Products, (No Diagnostic Substances)

Industry: Biotechnology

Vericel Corporation logo

Vericel Corporation

NASDAQ:VCELHealthcare
-6.18%$40.26
AH$40.26+0.00%vs close
Mkt Cap$2.06B
Float47.31M
O/S51.21M
Vol
$ Vol
RVOL
Inst Own-
SI11.1%
Earnings
Dilution
Vericel Corporation logoNASDAQ:VCEL$40.26-6.18%
Phase Distribution
14 lead-sponsored trials·2 active·10 completed
Phase 1/22
Phase 24
Phase 35
Phase 41
Not applicable2
(1 more as collaborator)
Status Overview
Recruiting2
Completed10
Stopped2

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 4
    Completed

    Study of the Treatment of Articular Repair (STAR)

    Carticel (autologous cultured chondrocyte) implantation

    Articular Cartilage

    Enrollment
    126
    Start
    Mar 2000
    Primary Completion
    Nov 2005
    Completion
    Nov 2005
    NCT00158613
  • Phase 3
    Completed

    Ixmyelocel-T Treatment of Patients With Osteonecrosis of the Femoral Head

    Ixmyelocel-T

    Osteonecrosis

    Enrollment
    11
    Start
    Sep 2007
    Primary Completion
    Sep 2010
    Completion
    Dec 2010
    NCT00505219
  • Phase 3
    Completed

    Superiority of MACI® Versus Microfracture Treatment in Patients With Symptomatic Articular Cartilage Defects in the Knee

    autologous cultured chondrocytes on porcine collagen membrane

    Articular Cartilage Defect

    Enrollment
    144
    Start
    Jul 2008
    Primary Completion
    Mar 2012
    Completion
    Mar 2012
    NCT00719576
  • Phase 3
    Completed

    An Efficacy and Safety Study of Ixmyelocel-T in Patients With Critical Limb Ischemia (CLI)

    Ixmyelocel-T

    Critical Limb Ischemia

    Enrollment
    41
    Start
    Feb 2012
    Primary Completion
    Mar 2014
    Completion
    Mar 2014
    NCT01483898
  • Phase 3
    Recruiting

    A Study of MACI in Patients Aged 10 to 17 Years With Symptomatic Chondral or Osteochondral Defects of the Knee

    MACI

    Chondral Defect, Osteochondritis Dissecans (OCD) +2

    Enrollment
    45
    Start
    Oct 2018
    Primary Completion
    Feb 2030est.
    Completion
    Feb 2030est.
    NCT03588975
  • Phase 3
    Recruiting

    A Study of MACI in Patients Aged 17 to 65 Years With Symptomatic Chondral or Osteochondral Defects of the Ankle

    autologous cultured chondrocytes on porcine collagen membrane

    Chondral Defect, Articular Cartilage Defect

    Enrollment
    309
    Start
    May 2026
    Primary Completion
    Jul 2030est.
    Completion
    Jul 2030est.
    NCT06915233
  • Phase 2
    Completed

    Use of Ixmyelocel-T (Formerly Vascular Repair Cells [VRC]) in Patients With Peripheral Arterial Disease to Treat Critical Limb Ischemia

    Ixmyelocel-T, Placebo

    Peripheral Arterial Disease

    Enrollment
    86
    Start
    Apr 2007
    Primary Completion
    Mar 2011
    Completion
    Mar 2011
    NCT00468000
  • Phase 2
    Completed

    Use of Ixmyelocel-T (Formerly Cardiac Repair Cell [CRC] Treatment) in Patients With Heart Failure Due to Dilated Cardiomyopathy (IMPACT-DCM)

    Ixmyelocel-T

    Dilated Cardiomyopathy

    Enrollment
    40
    Start
    Sep 2008
    Primary Completion
    Sep 2012
    Completion
    Sep 2012
    NCT00765518
  • Phase 2
    Completed

    Use of Ixmyelocel-T (Formerly Catheter-based Cardiac Repair Cell [CRC]) Treatment in Patients With Heart Failure Due to Dilated Cardiomyopathy

    Ixmyelocel-T

    Dilated Cardiomyopathy

    Enrollment
    22
    Start
    Dec 2009
    Primary Completion
    Jan 2012
    Completion
    Dec 2013
    NCT01020968
  • Phase 2
    Completed

    An Efficacy, Safety and Tolerability Study of Ixmyelocel-T Administered Via Transendocardial Catheter-based Injections to Subjects With Heart Failure Due to Ischemic Dilated Cardiomyopathy (IDCM)

    ixmyelocel-T

    Ischemic Dilated Cardiomyopathy (IDCM)

    Enrollment
    114
    Start
    Feb 2013
    Primary Completion
    Feb 2016
    Completion
    Mar 2018
    NCT01670981
  • Phase 1/2
    Terminated

    Feasibility Study of Aastrom Tissue Repair Cells to Treat Non-Union Fractures.

    Cultured Bone Marrow Tissue

    Fracture, Ununited, Pseudarthrosis

    Enrollment
    36
    Start
    Oct 2003
    Primary Completion
    -
    Completion
    Jun 2007
    NCT00424567
  • Phase 1/2
    Terminated

    Use of TRC Autologous Bone Marrow Cells in Posterolateral Lumbar Spine Fusion

    Bone Repair Cells (BRCs)

    Single Level Posterolateral Spinal Fusion

    Enrollment
    2
    Start
    Apr 2006
    Primary Completion
    Aug 2006
    Completion
    Oct 2008
    NCT00797550
  • Observational
    Completed

    The Objectives of the Cartilage Repair Registry is to Report Long Term Efficacy and Safety of Cartilage Repair Procedures in Registry Patients

    Carticel (autologous cultured chondrocyte) implantation

    Articular Cartilage, Cartilage Diseases

    Enrollment
    2,233
    Start
    Mar 1995
    Primary Completion
    Jan 2009
    Completion
    Jan 2009
    NCT00140634
  • Observational
    Completed

    Extension Study for Participants of MACI00206 Study of MACI® for the Treatment of Symptomatic Articular Cartilage Defects of the Knee

    autologous cultured chondrocytes on porcine collagen membrane

    Articular Cartilage Defects

    Enrollment
    128
    Start
    Dec 2010
    Primary Completion
    Mar 2015
    Completion
    Mar 2015
    NCT01251588
Search ClinicalTrials.gov for “Vericel”